THE CASE FOR A 100 DAY MISSION
Imagine a scenario where COVID-19 had hit, but the world was ready. A scenario where:
A responsive diagnostics sector swung into action, producing accurate and rapid diagnostic tests at scale to detect new cases early, monitor contacts, and guide critical public health intervention.
The research and development had already been completed and prototype diagnostics and therapeutics only needed tweaking before they could be subjected, along with vaccines, to rapid assessment through an established international clinical trials network to quickly affirm their safety and efficacy.
Global manufacturing capacity was there and swiftly activated, ready to produce accurate diagnostics quickly and therapeutics and vaccines at scale to those who need them.
The World Health Organization (WHO), upon declaring a Public Health Emergency of International Concern (PHEIC), enacted agreed protocols setting out the ‘rules of the road’ for a pandemic, speeding up data sharing and regulatory approvals and triggering procurement pools for diagnostics, therapeutics and vaccines (DTVs).
There was sufficient financing available, and ready to draw down, to get DTVs to the poorest countries at the scale needed.
In this scenario, the world could have deployed safe and effective DTVs in May 2020, and hundreds of thousands of lives would have been saved, lockdowns would have been shortened, and trillions of dollars of lost economic output saved.
In the first 100 days from a pandemic threat being identified (defined by when WHO declares a PHEIC) we should aim for the following interventions to be available, safe, effective and affordable:
Accurate and approved rapid point of care Diagnostic tests;
https://www.gov.uk/government/publications/100-days-mission-to-respond-to-future-pandemic-threats
Health and Social Care Secretary speech at the CEPI Global Pandemic Preparedness Summit 2022
The Secretary of State for Health and Social Care, Sajid Javid, spoke at the summit on Tuesday 8 March 2022
But just because we are starting to turn the tide on this virus, thanks to the protection that the vaccines have provided, it does not mean that we should take our foot off the accelerator.
We still face the threat of new COVID variants that could be more severe. They could be more transmissible or they could even escape the protection of current vaccines and when it comes to future pandemics it is a question not of if but when.
This is the ethos behind the 100 Day Mission – a vital partnership looking at how we can make diagnostics and therapeutics and vaccines more available, more effective, more affordable within the first 100 days of any new pandemic being identified.
https://www.gov.uk/government/speeches/health-and-social-care-secretary-speech-at-the-cepi-global-pandemic-preparedness-summit-2022
You are no better Prolee, each buy has a seller, each sell has a buyer. In other words it is always both whether shown red or blue.
simple rule, to buy someone must sell, to sell someone must buy, remove one from the transaction and there is NO transaction. It is always a simultaneous buy and sell.
“What does that mean? It means that C12 variant has somehow mutated so fast and far that it is now the furthest mutated variant found to date. It has mutated the greatest genetic distance from the original Wuhan 1.0 strain – and implies potential troubles for 1.0 vaccines,’’ he said.
“It gets worse with C12. It has a 1.7x to 1.8x faster mutation rate than the average of all other variants. The authors note this coincides with the emergence pattern of other really bad VOC variants.
“Consider this a hurricane warning on the next potential variant.”
While the new study is yet to be peer-reviewed, experts say the discovery underlines the risks of abandoning the basics of infection control.
https://www.google.co.uk/amp/s/www.news.com.au/lifestyle/health/health-problems/doomsday-covid-variant-detected-in-south-africa-even-worse-than-delta-strain/news-story/cd272bb749122954f3e58322be40be53%3famp
A bit rich coming from you Prolee, you’ve been aiding TB in negative posts to sway opinion thus helping TB get back in on the cheap.
It was easy to see what TB was doing, it’s actually 3 or so million more shares than planned since 2020, probably because the shareprice was stubbornly holding up prior to a token sale telling the market.. ‘no news due’ and down she slid. He got back in in a hurry though.. perhaps a at few pence higher than planned?
Carl has been spending time fine tuning our device, TB took advantage, simple as that. The device will be a market leader, is it too late? Nope! Far from it.. and the beauty is it’s not just for Covid.. it is a future proof muti use ground breaking all rounder for multiple markets, sepsis stands out by a mile.
GL all.. winds are changing once again.
Previously there had been no data on the accuracy of the Innova/NHS lateral flow test in UK schoolchildren. This study used the Orient Gene test, which is thought to be more sensitive than Innova, and identified only 32 of the 60 cases in school contacts, so its sensitivity is only 53%, said Deeks.
“This illustrates the risk of using lateral flow tests, which can only detect high viral levels, to check whether contacts are infected,” he said. “As those that the test missed were close contacts, they are likely to have been in the early stages of infection when viral levels are rising fast and the students are becoming infectious.”
https://www.bmj.com/content/374/bmj.n1878
Totally agree, for Covid alone it will be an all rounder. capabilities of a PCR, Lateral Flow, Antigen test in one.
https://pharmaphorum.com/views-and-analysis/covid-19-antibody-tests-integrated-approach/
Scientists say they have detected irregularities in the blood of long Covid patients that could one day pave the way for a test for the condition.
Imperial College London researchers found a pattern of rogue antibodies in the blood of a small number of people with long Covid.
They hope it could lead to a simple blood test within six to 18 months.
https://www.google.co.uk/amp/s/www.bbc.co.uk/news/health-57776010.amp
I think it will be quicker than that :-) Design Aptamers for the autoantibodies and boom.
The answer to that is no, no one can except Mr Brown himself. We can all guess, have differing opinions, but for facts we only really have RNS’s and annual reports.
The biggest clue as to what may happen, in my opinion, is something to do with 10 million additional shares (resulting in 20% of the company) earmarked for what must be the remuneration policy because the company has a surplus of cash.
‘The Remuneration Committee provides a formal and transparent review of the remuneration of the Executive Directors and senior employees and makes recommendations to the Board on individual remuneration packages. This includes the award of non-contractual performance related bonuses and share options. Remuneration packages are designed to reward, motivate, retain and recruit individuals. Bonuses are only paid in recognition of performance. The committee comprised Jonathan Freeman (Chairman) and Trevor Brown (CEO). No Director took part in discussions concerning the determination of their own remuneration.’
I am edging towards a combination of both a share bonus and options. Options need cash. Let’s face it, I would sell all my shares if I knew I could purchase twice as many via an options package. Remember, the directors wage bill is very low. £70k a year so expect them to churn.
Sadly yes, here is a link..
There are, on average, about 38 amputations a day due to sepsis and about 1% of sepsis survivors undergo one or more surgical amputations of a limb or digit as a result of sepsis. This could be one limb on a patient or multiple fingers/toes and limbs.
https://www.sepsis.org/sepsisand/amputations/
Morning Kainos, Starknight appears to be having a break but for what it is worth I’ll give you my thoughts.
The device mooted should be, there or thereabouts as quick as the Covid test (under 2 mins) as accurate as the Covid test (better than PCR as per the recent RNS whilst also capable of seeing the onset of the condition - below just 100 virions in a sample- previous RNS) with platform tech (detect multiple targets) enabling the device to label and identify the exact type of sepsis (50 most common mentioned as an example) offering incredible accuracy (option for quantification of viral load) enabling the end user to immediately choose the correct remedy and I’m guessing dose rather than the current hope and experimentation which will drastically improve outcomes, not only from a live/die situation, but also a quality of life for the patient as the speed and accuracy offered should also prevent other life changing outcomes such as limb removals.
As Sepsis is a common outcome from the Covid infection and most likely many other infections, hospitalised patients could be monitored for Sepsis offering a level of prevention of the onset of sepsis by nipping it in the bud very accurately and very early. However, that all depends on policies of the end user actively seeking it.
What happens when Government Policy relies on the Public?
Findings 'deeply disappointing'
The NAO warned effectiveness of the service was still being undermined by low levels of public compliance, both in terms of coming forward for testing and adhering to isolating.
It also pointed out that just 14% of the 691 million rapid tests sent out to the public had been registered as used.
https://www.google.co.uk/amp/s/www.bbc.co.uk/news/health-57601097.am
Self testing continues to fail the NHS test and trace program in many ways with even greater issues than accuracy, drastic changes are required!
A super quick, super accurate, on site test that can be trusted by the public which has been robustly tested by independent 3rd parties in real world settings offering public confidence is desperately required.
Looking good here to meet the above.
A single route to evaluate new diagnostic tests for COVID-19
CONDOR is accelerating how quickly promising COVID-19 diagnostics make it into real-world use. The platform is evaluating new COVID-19 diagnostics in the settings they will be used, such as in GP surgeries, care homes or hospitals, as well as their performance in laboratory settings.
These tests will be used to support diagnosis and management of patients with suspected COVID-19, and collect data to help develop effective diagnostic pathways for subsequent waves of infection in the post-pandemic setting.
https://www.condor-platform.org
“distinguish between intact viral particles and residual RNA fragments. It is known that RNA fragments are present in nasal and pharyngeal epithelial cells and can yield a positive PCR test result for several weeks after peak viral load has passed.“
I think this confirms we are challenging the global gold standard PCR test.